T1	Participants 580 699	patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronat
T2	Participants 305 365	different subgroups with glucocorticoid-induced osteoporosis
T3	Participants 869 1292	Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (â‰¤ 3 months) subpopulations]were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use
